Table 2. Current clinical-stage PROTACs

Compound	Target protein	Indication	Reference
ARV-110	AR	Metastatic castration-resistant prostate cancer	[65]
ARV-766	AR	Metastatic castration-resistant prostate cancer	[66]
ARV-471	ER	Breast cancer (ER+/HER2-)	[67]
DT2216	BCL-XL	Hematologic malignancies, solid tumors	[68]
NX2127	BTK, IKZF1/3	CLL, NHL	[69]
NX5948	BTK	B-cell malignant tumors and autoimmune diseases	[70]
CFT 1946	Mutant BRAF V600E	Melanoma, colorectal cancer	[71]
CFT 8634	Bromodomain-containing protein 9	Synovial sarcoma	[72]
CFT 8919	Mutant EGFR L858R	Non-small cell lung cancer	[73]
KT-474	IRAK4	Autoimmune diseases	[74]

PROTACs, proteolysis-targeting chimeras; AR, androgen receptor; ER, estrogen receptor; BCL-XL, B-cell lymphoma-extra large; BTK, Bruton tyrosine kinase; IKZF, ikaros; CLL, chronic lymphocytic leukemia; NHL, non-hodgkin’s lymphoma; BRAF, B-Raf proto-oncogene, serine/threonine kinase; EGFR, epidermal growth factor receptor; IRAK4, interleukin-1 receptor-associated kinase 4.